Compare
Incyte Corp vs Charles River Laboratories International, Inc. vs Icon PLC vs Iqvia Holdings Inc.
| Latest fiscal year | Incyte Corp INCY | Charles River Laboratories International, Inc. CRL | Icon PLC ICLR | Iqvia Holdings Inc. IQV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-27 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.14B | $4.02B | $8.25B | $16.31B |
| Revenue growth (YoY) | +21.2% | -0.9% | +0.8% | +5.9% |
| Gross margin | 92.8% (computed) | n/a | n/a | n/a |
| Operating margin | 29.5% | 0.6% | 5.4% | 13.4% |
| Net margin | 25.0% | -3.5% | 2.8% | 8.3% |
| Net income | $1.29B | -$142.16M | $229.34M | $1.36B |
| EPS (Diluted) | $6.41 | -$2.91 | $2.90 | $7.84 |
| Operating cash flow | $1.41B | $737.65M | $1.04B | $2.65B |
| Free cash flow | n/a | $518.49M | $861.99M | $2.05B |
| Cash & equivalents | $3.10B | $213.77M | $647.29M | $1.98B |
| Total assets | $6.96B | $7.14B | $16.27B | $29.94B |
| Total liabilities | $1.79B | $3.92B | $7.08B | $23.31B |
| Shareholders' equity | $5.17B | $3.17B | $9.19B | $6.63B |
| Return on year-end equity | 24.9% | -4.5% | 2.5% | 20.5% |
| Shares outstanding | 198.46M | 49.22M | 76.57M | 169.60M |
Revenue, most recent five fiscal years
| Fiscal year | Incyte Corp | Charles River Laboratories International, Inc. | Icon PLC | Iqvia Holdings Inc. |
|---|---|---|---|---|
| Latest | $5.14B Ended 2025-12-31 | $4.02B Ended 2025-12-27 | $8.25B Ended 2025-12-31 | $16.31B Ended 2025-12-31 |
| 1 year earlier | $4.24B Ended 2024-12-31 | $4.05B Ended 2024-12-28 | $8.19B Ended 2024-12-31 | $15.40B Ended 2024-12-31 |
| 2 years earlier | $3.70B Ended 2023-12-31 | $4.13B Ended 2023-12-30 | $8.05B Ended 2023-12-31 | $14.98B Ended 2023-12-31 |
| 3 years earlier | $3.39B Ended 2022-12-31 | $3.98B Ended 2022-12-31 | $7.74B Ended 2022-12-31 | $14.41B Ended 2022-12-31 |
| 4 years earlier | $2.99B Ended 2021-12-31 | $3.54B Ended 2021-12-25 | $5.48B Ended 2021-12-31 | $13.87B Ended 2021-12-31 |